Eli Lilly's Dual-Pronged Offensive: Skin-Drug Approval and GLP-1 Data Reinforce Pipeline Strength

FDA expands EBGLYSS label to every-two-month dosing for atopic dermatitis; oral GLP-1 Orforglipron beats Novo Nordisk in phase 3; Retatrutide shows 28% weight loss. Stock near €1,044 peak.

Eli Lilly is demonstrating the breadth of its research engine with two distinct catalysts emerging in quick succession. While the market’s gaze has been fixed on the obesity race, the company has quietly secured a regulatory win in dermatology and released clinical results that underscore its lead in the GLP-1 arena. The stock, which closed near €991 on Tuesday, is hovering just 5% shy of its all-time high of €1,044 – a level that looks increasingly vulnerable.

The U.S. Food and Drug Administration has granted an expanded label for EBGLYSS, Lilly's biologic for moderate-to-severe atopic dermatitis. The key change: patients who respond to initial therapy can now stretch their maintenance injections from once a month to once every two months. That cuts the annual burden to just six shots, a significant quality-of-life improvement for adults and adolescents aged 12 and older weighing at least 40 kilograms. The decision was backed by the ADjoin extension study, in which no patient discontinued due to adverse events over 32 weeks. Known side effects such as conjunctivitis and injection-site reactions remained manageable, and no new safety signals emerged. With exclusive U.S. marketing rights, Lilly now holds a dosing advantage that could drive prescription volume.

On the metabolic front, Lilly's oral GLP-1 candidate Orforglipron (brand name Foundayo) has posted head-to-head data that leaves Novo Nordisk in its wake. The phase 3 ACHIEVE-3 trial tested a 17.2-mg dose against Novo's oral semaglutide at 14 mg over 52 weeks. Foundayo produced a 2.2% reduction in HbA1c versus 1.4% for the competitor, and a 73.6% greater weight loss. The smaller ACHIEVE-2 study also showed superiority over the SGLT2 inhibitor dapagliflozin, while ACHIEVE-5 confirmed efficacy against placebo. Lilly has confirmed it will file for FDA approval in type 2 diabetes as early as the second quarter of 2026.

Adding to the narrative, the company’s next-generation candidate Retatrutide delivered a striking 70-pound average weight loss – roughly 28% of body weight – at the highest 12-mg dose over 80 weeks. Beyond the scale, patients reported improvements in knee osteoarthritis pain, sleep apnea, and blood pressure. These data points strengthen Lilly's hand in what is becoming a crowded oral GLP-1 field, with several competitors racing to catch up.

At the market close, Lilly shares stood at €987.20, down 1.1% on the day but still up more than 17% from their 50-day moving average of €844.68. The month-to-date gain remains a robust 20%. The relative strength index of 67.7 suggests the stock is in overbought territory but without flashing warning signs. Over the past twelve months, the equity has rallied over 45%, driven by obesity-drug momentum and pipeline breadth.

Lilly’s parallel build-out of its immunology franchise – now anchored by EBGLYSS with its flexible dosing – gives the company a second growth engine alongside its metabolic portfolio. The FDA nod reduces the treatment burden for patients and could accelerate market share gains in a competitive atopic dermatitis landscape. Meanwhile, the steady drumbeat of positive GLP-1 data reinforces the investment case. The coming months will test whether Foundayo’s regulatory filing can provide the next upward catalyst, or if the stock will first digest its recent run before resuming its ascent.